Review compares patient-important outcomes and assesses evidence among 42 systemic treatments in patients in 93 studies.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Dupilumab (Dupixent; Sanofi/Regeneron) has been approved to treat moderate to severe AD in children aged 6 months and older as well as in children who have asthma and eosinophilic esophagitis.

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Children treated with dupilumab also experienced improvements in seven other endpoints, Mirna Chehade, MD, MPH, professor of pediatrics and medicine at Icahn News News CME CME ...

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. New England Journal of Medicine , 2021; 385 (24): 2230 DOI: 10.1056/NEJMoa2106567 Cite This Page : ...

Serious adverse events remained rare and skin remained largely clear in adolescents treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis (AD) for up to 52 weeks in a phase 3 ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Dupilumab is an effective and safe treatment option for patients with atopic dermatitis (AD) in real-life settings, including those with malignancy and other medical comorbidities, ...

Dupilumab was added as an active comparator in the trial because its efficacy has been shown in this population and it was previously evaluated in a similarly designed proof-of-concept study. 6,7 ...